Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial

AIDS Research and Human Retroviruses

Volumn 27, Issue 1, 2011, Pages 29-34

  Fox, Julie ^a   Peters, Barry ^a   Prakash, Manyu ^b   Arribas, Jose ^c   Hill, Andrew ^d   Moecklinghoff, Christiane ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b JANSSEN CILAG GMBH   (Germany)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR PLUS SAQUINAVIR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNIC DIFFERENCE; EUROPE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RACE DIFFERENCE; SCREENING TEST; SEASON; SEX DIFFERENCE; SIDE EFFECT; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 78651464000     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2010.0081     Document Type: Article

References (24)

1. Tsoukas C, Provvedini D, and Manolagas S: 1,25-Dihydroxyvitamin D3: A novel immunoregulatory hormone. Science 1984;224:1438-1440.
2. Ceglia L: Vitamin D and its role in skeletal muscle. Curr Opin Clin Nutr Metab Care 2009;12:628-633.
3. Grant W and Holick M: Benefits and requirements of vitamin D for optimal health: A review. Altern Med Rev 2005; 10:94-111.
4. Welz T, Childs K, Ibrahim F, Poulton M, and Post F: Efavirenz use is associated with severe vitamin D deficiency in a large, ethnically diverse urban UK HIV cohort. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22, 2009. Cape Town. Abstract TUPEB186. http:// www.iasociety.org/Default.aspx?pageId'11&abstractId' 200722658.
5. National Cancer Institute Factsheet: Vitamin D and cancer prevention: Strengths and limitations of the evidence. Available online at factsheet/prevention/vitamin-D.
6. Lappe J, Travers-Gustafson D, Davies K, Recker R, and Heaney R: Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-1591.
7. Wactewski-Wende J, Kotchen J, Anderson G, Assaf A, Brunner R, O'Sullivan M, et al.: Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:684-696. (Pubitemid 43247139)
8. Autier P and Gandini S: Vitamin D supplementation and total mortality: A meta-analysis of randomized controlled trials. Arch Intern Med 2007;167(16):1730-1737.
9. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, et al.: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: Effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24:1375-1382.
10. Brown T and McComsey G: Association between initiation of antiretroviral therapy with efavirenz and decreases in 25 hydroxyvitamin D. International Workshop on Adverse Events and Lipodystrophy, Philadelphia, October 2009 [abstract].
11. Rodríguez M, Daniels B, Gunawardene S, and Robbins GK: High frequency of vitamin D deficiency in ambulatory HIVpositive patients. AIDS Res Hum Retroviruses 2009;25:9-14.
12. Mehta S, Giovannucci E, Muguzi F, Spiegelman D, Aboud S, Hertzmark E, et al.: Vitamin D status of HIV-infected women and its association with HIV disease progression, anaemia and mortality. PLoS One Med 2010;5 (1):e8770 (1-7).
13. Arribas J, Horban A, Gerstoft J, Fatkenheuer G, Nelson M, Clumeck N, et al.: The MONET Trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mL. AIDS 2010;24:223-230.
14. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, and Dusso AS: HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003;17:513-520.
15. Dao C, Patel P, Pals S, Bush T, Rhame F, Overton T, and the SUN Study Investigators: Assessment of vitamin D levels among HIV-infected persons in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study). 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010 [abstract 750].
16. Borderi M, Vescini F, Cozzi-Lepri A, Di Caro A, Shlacht I, and Cassola G for the Icona Study Group: Prevalence of hypovitaminosis D among HIV' patients enrolled in a large Italian cohort. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010 [abstract 751].
17. Mueller N, Fux C, Ledergerber B, Elzi L, Schmid P, Dang T, et al.: High prevalence of severe vitamin D deficiency in cART naive and successfully treated Swiss HIV patients.
18. Canadian Cancer Society 2007. Canadawide/About%20us/Media%20centre/CW- Media% 20releases/CW2007/ Canadian%20Cancer%20Society%20Announces%20Vitamin%20D%20Recommendation.aspx?sc- lang'en Accessed November 2009.
19. Brown T and Qaqish R: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS 2006;20:2165-2174.
20. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, and da Silva BA: Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009;51: 554-561.
21. Wang T, Pencina M, Booth S, Jacques P, Ingelsson E, Lanier K, et al.: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-511.
22. Bair T, May H, Horne B, Lappe D, Carlquist J, Ronnow B, et al.: Vitamin D deficiency is strongly associated with incident death and cardiovascular disease in a general healthcare population. Circulation 2009;120:S455 [abstract 1147].
23. Melamed M, Michos E, Post W, and Astor B: 25- Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168(15):1629-1637.
24. Childs K, Kadish C, Branch-Elliman W, Fishman S, Mullen M, and Branch A: Vitamin D and calcium supplements reverse the secondary hyperparathyroidism that commonly occurs in HIV patients on TDF-containing HAART. 15th Annual Conference of the British HIV Association, Liverpool, United Kingdom, April 2009 [abstract P89].